natgillin/translations-raw huggingface dataset:
Compounds, compositions and methods 
SPOJEVI, PRIPRAVCI I METODE
The method of claim 1, wherein a 1-bit syntax element is used to indicate whether the current Intra mode for the current block is equal to a first MPM of said three MPMs. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se 1-bitni sintaksni element upotrebljava za ukazivanje je li trenutačni Intra mod za trenutačni blok jednak prvom MPM od navedena tri MPM.
wherein each rotor has a driving means; rotating the rotors; wherein the first rotor rotates to give an acceleration field of from 25 to 60 km/s2 and the second and third rotors each rotate to give an acceleration field of at least 125 km/s2, 
Totiranje rotora; pri čemu se prvi rotor rotira kako bi stvorili polje za ubrzanje od 25 do 60 km/s", i drugi i treći rotor se rotira kako bi stvorili polje ubrzanja od najmanje 125 km/s", osiguravajući mineralnu rastaljenu tvar, pri čemu ta mineralna rastaljena tvar ima rastopinu koji ima slijedeći sastav izražen prema masi oksida:
This may be done in different ways. 
Ovo se može napraviti na različite načine.
Total Layer Weight 
/Ukupna masa sloja
The first and second engage members 14, 15 are located outside the area 11 enclosed by the endless track 4 and the third engage member 16 is located inside said area 11. 
Prijenosni uređaj prema bilo kojem zahtjevu 1-6., naznačen time da su prvi i drugi zahvatni član (14, 15) smješteni izvan područja okruženog beskonačnom stazom (4) 1 treći zahvatni član (16) je smješten unutar rečenog područja.
each Rc3 is selected from hydrogen; and alkyl; 
je odabran od vodika; alkila; alkenila; i alkinila;
The compound according to any one of claims 1 to 9 for use in the treatment or prevention of a neurological condition preferably selected from the group consisting of Alzheimer's disease, multiple sclerosis, cognitive disorders, memory disorder, depressive disorders, bipolar disorder and schizophrenic disorders, Parkinsons' disease, Huntington's disease, vascular dementia, fronto-temporal dementia, Lewy bodies dementia, Creutzfeld-Jacob disease, epilepsy, migraine, anxiety, panic, psychosis, hypersensitive syndrome and pain. 
13. Spoj prema bilo kojem od zahtjeva 1 do 9 za uporabu u liječenju ili prevenciji neurološkog stanja poželjno izabranog iz grupe koja obuhvaća Alzheimerovu bolest, multiplu sklerozu, kognitivne poremećaje, poremećaj pamćenja, depresivne poremećaje, bipolarni poremećaj 1 shizofrene poremećaje, Parkinsonovu bolest, 10
A pharmaceutical composition as in clause 1, wherein the composition is formulated to increase the residence time of rifaximin in the gastrointestinal tract. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 1, naznačen time da je taj pripravak formuliran na način da se produlji vrijeme zadržavanja rifaksimina u probavnom sustavu.
EDMAB ethyl 4-dimethylaminobenzoate, are kept separate until use, where the two resins are mixed together. 
EDMAB etil-4-dimetilaminobenzoat su čuvani zasebno do upotrebu, kad su dvije smole zajedno pomiješane.
and wherein the inflammatory-related disease is selected from the group consisting of: diabetes type I; Sjorgen's syndrome; uveltis; allergic conjunctivitis; cellac disease; and non-specific colitis. 
i pri čemu je bolest povezana s upalom odabrana iz skupine koju čine: upalna bolest crijeva; reumatoidni artritis; te lupus.
The method of claims 1 to 7, wherein the first composition further comprises a (±)-A9-tetrahydrocannabinol seed crystal. 
Postupak prema zahtjevima 1 do 7, naznačen time da prvi sastav nadalje sadrži kristalni zametak (±)-A9-tetrahidrokanabinola.
In another further example, the formulation comprises a glidant, such as colloidal silicon dioxide. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 6, naznačena time što je sredstvo za klizanje 0,1% do 2,0%, težinski, koloidni silicijev dioksid.
was hydrogenated over 8 grams of 5% Pd/C catalyst at atmospheric pressure and room temperature until hydrogen uptake ceased (about 24 hours). 
hidrogenzira se preko 8 grama 5% Pd/C katalizatora na atmosferskom tlaku i sobnoj tempcraturi dok ne prestane potrošnja vodika (oko 24 sata).
A composition comprising the antibody, or antigen binding portion thereof, of claim 25, and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži antitijelo iz bilo kojeg od patentnih zahtjeva 1-11, i farmaceutski prihvatljiv nosač.
A fusion peptide according to claim 12 or 13, wherein component (III) comprises at least 4, preferably at least 10, more preferably at least 20 additional amino acid residues of the N-terminal sequence of GLP-2 as in proglucagon or of GLP-1(7-37). 
Fuzijski peptid prema patentnom zahtjevu 9 ili 10, naznačen time da komponenta (III) obuhvaća najmanje 4, poželjno najmanje 10, a još poželjnije najmanje 20 aminokiselinskih ostataka N-terminalne sekvence od GLP-2 kao u proglukagonu ili od GLP-1(7-37). t>&
The above described process steps are comprised by the so-called "European method" or "North American method" for the manufacture of veneers. 
Gore opisane faze postupka su obuhvaćene u tako zvanom "europskom postupku" ili u "sjeverno američkom postupku" za proizvodnju furnira,
A compound having the formula: A pharmaceutical formulation comprising the compound of claim 15 and a pharmaceutically acceptable excipient, carrier, or diluent. 
Farmaceutska formulacija, naznačena time, da sadrži spoj iz patentnog zahtjeva 1 farmaceutski prihvatljiv ekscipijens, nosač ili razrjeđivač.
The pressure inside the capsule assists in the opening of an outlet face of the capsule. 
- < tlak unutar čahure pomaže pri otvaranju ispusne plohe čahure;
Preferably the particular conformation in which the GPCR resides in step (c) corresponds to the class of ligand selected in step (b). 
Metoda iz Zahtjeva 1-15 naznačena time da korak (c) obuhvaća primjenu rezonantnog prijenosa energije fluorescencije (FRET).
Het3 represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het3 is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C1-4alkyl-; 
Het3 predstavlja heterocikal odabran od morfolinil, piperazinil, piperidinil ili pirolidinil pri čemu navedeni Het3 je proizvoljno supstituiran sa jednim ili gdje je moguće sa dva ili više supstituenata koji su odabrani iz skupine koja sadrži hidroksi, amino ili C1-4alkil-;
The use according to any preceding claim, wherein the initial period of treatment is selected from the group consisting of: up to 10 days, 5 to 14 days, and 4-12 days. The use according to any one of the preceding claims wherein the daily dosage is raised stepwise up to 6 times up to the standard daily dosage and thereafter the treatment is continued with the standard daily dosage. 
Tvar u skladu s patentnim zahtjevom 1 za uporabu u liječenju u skladu s patentnim zahtjevom 1, pri čemu je trajanje početnog razdoblja liječenja odabrano iz grupe koja se sastoji od: 4 do 12 dana, 5 do 14 dana, do 10 dana, 7 do 10 dana, 9 dana, 8 dana, 7 dana, 6 dana, 5 dana ili 4 dana.
The compound of claim 1, wherein R1 is hydroxyl, methoxy, amino or methoxycarbonylamino, and R2 is hydrogen, phenyl or fluorophenyl. 
R! je hidroksil, metoksi, amino ili metoksikarbonilamino, a R? je vodik, metil, fenil ili fluorfenil.
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and 
Kombinacija: (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegova farmaceutski prihvatljiva sol ili hidrat spoja ili soli; te
The compound of Claim 1 wherein a is 1 or 2. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da a je 1 ili 2.
In certain embodiments, the modified nucleobase is 5-methylcytosine. 
€) - modificirana nukleobaza je 5-metilcitozin.
The method according to claim 7, characterized in that telmisartan of form A is crystallized at a temperature of -10 to + 10°C. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se telmisartan oblika A kristallizira pri temperaturi od -10 do + 10°C.
The measured crystals were fixed with inert perfluoro-oil to the tip of a Lindemann-glass capillary and transferred into the cold nitrogen stream on a Nonius KappaCCD on rotating anode. 
Kristali koji su mjereni pričvršćeni su s inertnim perfluoro-uljem za vrh Lindeman-staklene kapilare i preneseni u hladnu struju dušika na Nonius KappaCCD na rotirajuću anodu.
a second nucleic acid sequence comprising a transcribable nucleic acid sequence or a nucleic acid sequence for introducing the transcribable nucleic acid sequence wherein the transcribable nucleic acid sequence comprises a nucleic acid sequence coding for a peptide or protein; 
Molekula nukleinske kiseline koja sadrži u 5’→3’ smjeru transkripcije: promotor, transkriptabilnu sekvencu nukleinske kiseline ili sekvencu nukleinske kiseline za uvođenje transkriptabilne sekvence nukleinske kiseline,
M1(R1)m (IV) wherein M1 represents aluminium, magnesium, zinc, lithium; R1 represents a linear or branched C1-C20 alkyl group; m is 1, 2, or 3; 
Mi(Ri)m (IV) gdje M, predstavlja aluminij, magnezij, cink, litij; RI predstavlja linearnu ili razgranatu C,-C2o alkil grupu; m je 1, 2, ili 3;
at least an activating apparatus for moving said arm (21); 
barem aparat za aktiviranje za pokretanje navedenog kraka (21);
a third soluble CD40L cytokine domain, wherein each of the soluble CD40L cytokine domains lacks a stalk region. 
treću topljivu citokinsku domenu iz TNF obitelji, pri čemu se fuzijski polipeptid znatno ne agregira i pri čemu je topljiva citokinska domena iz TNF obitelji izabrana od topljivih TRAIL domena.
The bleb of claim 12 or composition of claim 13 or 14 for use in the manufacture of a medicament for preventing Shigella infection in a mammal. 
Vezikula u skladu s patentnim zahtjevom 12 ili pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačeni time što su namijenjeni upotrebi u proizvodnji medikamenta za sprečavanje zaraze uzrokovane bakterijom Shigella kod sisavca.
The present invention also relates to a method of producing a powder adhesive comprising the steps of: mixing expanded perlite, cement, and a dispersible polymer powder, in any order; wherein at least 30% volume of the sand-free powder adhesive is the expanded perlite. 
Pripravak ljepila bez pijeska koji sadrži: cement; disperzibilni polimerni prah; i prošireni perlit, pri čemu je najmanje 30% volumena ljepila bez pijeska prošireni perlit; naznačen time što je spomenuti cement u omjeru između 800-950% mase spomenutog proširenog perlita.
wherein the nucleotide sequence of interest is inserted into the host cell genome, and further wherein the transposon or transposase is optionally of a mariner-type, further optionally is Sleeping Beauty. 
gdje je nukleotidna sekvenca od interesa ubačena u genom stanice domaćina, i dodatno gdje je transpozon ili transpozaza izborno tipa mariner, dodatno izborno predstavlja „Sleeping Beauty“.
The device as claimed in claim 1, wherein at least one conductor layer (403) is provided between the heater (202) and the reaction chamber (201). 
Mikročip (10) prema zahtjevu 1, pri čemu se između reakcijske komore (11) baze i grijača (12) nalazi praznina veličine od 0,2 mm do 0,7 mm.
In certain embodiments, the ratio of the opioid agonist to the opioid antagonist is such that when the oral dosage form is tampered with to compromise the integrity of the particles comprising the opioid antagonist, an amount of the antagonist would be released that would substantially reduce or eliminate the euphoric effect of the opioid agonist when administered to a human subject orally, parenterally, intranasally and/or sublingually. 
Farmaceutski proizvod prema bilo kojem od prethodnih zahtjeva, naznačen time da čestice opioidnog antagonista imaju prosječan promjer od oko 0.1 do oko 6.0 mm, mnoštvo čestica poželjno ima prosječan promjer od oko 0.1 do oko 3 mm i/ili da je količina opioidnog antagonista oslobođenog nakon uzimanja izmiješanog oblika za doziranje učinkovita da blokira euforični učinak opioidnog agonista.
An antibody that is specific against the MHC/peptide complex of MHC with a peptide consisting of SEQ ID No. 9. 
Antitijelo specifično protiv kompleksa MHC/peptid MHC-a s peptidom koji se sastoji od SEQ ID No. 22. Komplet koji se sastoji od:
The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises a glucose lowering agent. 
Farmaceutski pripravak sukladno zahtjevu 10, naznačen time što farmaceutski pripravak sadrži sredstvo za snižavanje glukoze.
reducing the nitro moiety of compound of formula (3') to obtain compound of formula (4'); 
(ili) reduciranje nitro dijela spoja formule (3%) kako bi se dobio spoj formule (4?); t>& m» ll.
The presence of carboxyl group in the glucuronic acid moiety of the HA and the carbonyl and amino groups in the N-acetyl group of the glucosamine, as well as the hydroxyl groups being present facilitate the formation of several hydrogen bridges. 
Prisutnost karboksilne skupine u dijelu glukuronske kiseline HA i karbonilne i amino skupine u N-acetilnoj skupini glukozamina, kao i hidroksilne skupine koje su prisutne, doprinose formiranju nekoliko vodikovih mostova.
The method of claim 1, wherein said total amount of said produced TNFR-Ig is at least 1.5-fold higher that the amount of TNFR-Ig produced under otherwise identical conditions in otherwise identical medium that lacks said medium characteristic. 
Postupak prema Zahtjevu 1, gdje je spomenuta količina dobivenog TNFR-Fc najmanje 1,5-put veća nego količina dobivenog TNFR-Fc pod inače identičnim uvjetima, u inače identičnom mediju, kojem nedostaju spomenute karakteristike medija.
the time taken to be dry by touch, are less than about five minutes, preferably less than about two minutes. 
vrijeme koje je potrebno da je nešto suho na dodir, je manje od oko pet minuta, poželjno manje od oko dvije minute.
In certain embodiments, the condition is cancer, and in particular embodiments, the cancer is hematological cancer. In other particular embodiments, the condition is multiple myeloma, chronic lymnphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia., acute myeloid leukemia, chronic myeloid leukemia, B-cell lymphoma, or Burkitt's lymphoma. 
Izolirano protutijelo za uporabu u liječenju raka prema zahtjevu 9 naznačeno time da navedeni rak je hematološki rak i odabran je iz skupine koju čine multipli mijelom, kronična limfoblastična leukemija, kronična limfocitna leukemija, leukemija stanica plazme, akutna mijeloidna leukemija, kronična mijeloidna leukemija, limfom B stanica, i Burkittov limfom.
Ar is selected from the group consisting of Z4-14 aryl and C1-10 heteroaryl; 
Ar je odabran iz skupine koja sadrži Caja aril i Ci.19 heteroaril; mje 0, 1,2,3,1l14;
Referring now to Figures 4 to 8, container 10 is fabricated according to the invention in the following steps: 
Pozivajući se sada na slike 4 do 8, spremnik 10 se proizvodi u skladu s ovim izumom u sljedećim koracima:
Conductometer (Metrohm or equivalent); 
- < Konduktometar (Metzrohm ili njegov ekvivalent);
Spud-pile carriage according to Claim 1, in which the pivot pin (21) is at right angles to the spud-pile (8) and the direction of travel of the spud-pile carriage (1). 
Kolica za sidreni stup u skladu s patentnim zahtjevom 1, naznačena time što je os zakretanja (21) pod pravim kutom u odnosu na stup za sidrenje (8) i na smjer kretanja kolica za sidreni stup (1).
FIG. 2 shows a front view of the sampler shown in FIG. 
Slika 2 - prikazuje pogled s prednje strane na napravu za uzimanje uzorka, koja je prikazana na slici 1;
providing at least one anode, at least one cathode and at least one separator between the at least one anode and the at least one cathode; and 
- osiguravanje najmanje jedne anode, najmanje jedne katode i najmanje jednog separatora između najmanje jedne anode i najmanje jedne katode; i
In another embodiment, the multipurpose airway device is suitable for an adult, is larger than the child-suitable version and has an elliptical cross-section. 
Višenamjenski uređaj za disanje sukladno bilo kojem prethodnom zahtjevu, pri čemu je višenamjenski uređaj za disanje prikladan za odrasle, a cjevasto tijelo ima eliptični poprečni presjek; i eventualno pri čemu je vanjski konjugirani promjer cjevastog tijelo u rasponu između približno 15 150 mm, npr.
from 99 to 1 weight percent of one or more inorganic mineral fillers, 
jedno ili više anorganskih mineralnih punila u masenom postotku od 99 do 1;
low back pain, visceral pain or headache; and/or 
lumbalna bol, visceralna bol ili glavobolja; i/ili
The fungicidal composition according to claim 1, wherein (b) s at least one fungicide selected from the group consisting of bixafen, fluxapyroxad, penflufen, isopyrazam, fluopyram, ametoctradin and fenpyrazamine. 
najmanje jedan fungicid odabran iz skupine koja se sastoji od biksafena, fluksapiroksada, penflufena, izopirazama, fluopirama, fenpirazamina i sedaksana.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 61 and a second pharmaceutically active agent selected from the group consisting of aspirin, angiotensin II receptor antagonists, calcium channel blockers, beta-blockers, CI1027, CCR5 receptor antagonists, imidazolines, sGCa's (soluble guanylate cyclase activators) antihypertensive agents, diuretics, alpha adrenergic antagonists, ACE (angiotensin converting enzyme) inhibitors, aldosterone receptor antagonists, neutral endopeptidase inhibitors, antidiabetic agents, sulfonylureas, glitazones, cholesterol lowering agents, and alpha-2-delta ligands. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 61 i dodatno farmaceutski aktivno sredstvo, koje se bira iz skupine koju čine aspirin, antagonisti receptora angiotenzina II, blokatori kalcijskih kalnala, B-blokatori, CI1027, antagonisti receptora CCR*, imidazolini, antihipertenzivna sredstva tipa sGCa (topivi aktivatori gvanilat-ciklaze), diuretici, a-adrenergički antagonisti, inhibitori ACE (angiotenzin-konvertirajući enzim), antagonisti aldosteronskog receptora, inhibitori neutralne endopeptidaze, antidijabetička sredstva, sulfoniluree, glitazoni, sredstva za snižavanje razine kolesterola i a-2-8 ligandi.
Summary of the invention 
Kratki opis izuma
The composition for the use of claim 1, wherein the extranodal lymphoma includes central nervous system (CNS), cutaneous tissue, breast, lungs, liver, gastrointestinal tract, genitourinary tract, ocular tissue, bone marrow and/or bones. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što ekstranodalni limfom uključuje središnji živčani sustav (CNS), kutano tkivo, dojke, pluća, jetru, gastrointestinalni sustav, genitourinarni sustav, očno tkivo, koštanu srž i/ili kosti.
Y1, Y2, Y3 and Y4 are independently selected from the group consisting of carbon and nitrogen with the proviso that at least one of Y1, Y2, Y3 and Y4 is nitrogen; if Y1 is nitrogen then R6 is absent; 
Y', YZi Y" su neovisno izabrani iz skupine koju čine ugljik i dušik, pri čemu Y? je dušik i R* je odsutan; te ako Y' je dušik tada R* je odsutan;
The composition for use or polypeptide of claim 15 or 16, wherein the factor Xa inhibitor is selected from the group consisting of fondaparinux, idraparinux, biotinylated idraparinux, enoxaparin, fragmin, NAP-5, rNAPc2, tissue factor pathway inhibitor, DX-9065a, YM-60828, YM-150, apixaban, rivaroxaban, PD-348292, otamixaban, DU-176b, LY517717, GSK913893, razaxaban, low molecular weight heparin, betrixaban or a pharmaceutically acceptable salt thereof, and combinations thereof. 
Pripravak za uporabu prema zahtjevu 10 ili 11, naznačen time da je inhibitor faktora Xa odabran iz skupine koju čine fondaparinuks, idraparinuks, biotinilirani idraparinuks, enoksaparin, fragmin, NAP-5, rNAPc2, inhibitor faktora tkivnog puta, DX-9065a, YM-60828, YM-150, apiksaban, rivaroksaban, PD-348292, otamiksaban, DU-176b, LY517717, GSK913893, razaksaban, heparin niske molekularne težine, betriksaban ili njihova farmaceutski prihvatljiva sol, te njihove kombinacije.
or a pharmaceutically acceptable salt of any of the foregoing. 
Spojiiša, ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
A compound having a structure represented by formula (I) wherein 
Spoj koji ima strukturu predstavljenu formulom (1) gdje
21, 22, 23 or 24, and a light chain of sequence selected from the group consisting of SEQ ID Nos. 
21, 22, 23, 24, 89 ili 91 te sekvenciju lakog lanca odabranu iz sljedeće skupine: SEQ ID br.
the two brewing chambers, or 
- < dvije komore za kuhanje, ili
The composition for use of claim 1, wherein the method comprises administration of the composition via an intravenous, intraarterial, intraperitoneal, intravesicular, subcutaneous, intrathecal, intrapulmonary, intramuscular, intratracheal, intraocular, transdermal, oral, or inhalation route. 
Pripravak za upotrebu prema patentnom zahtjevu 1, naznačen time što postupak obuhvaća davanje pripravka putem intravenoznog, intraarterijskog, intraperitonealnog, intravezikularnog, potkožnog, mtratekalnog, intrapulmonalnog, intramuskularnog, intratrahealnog, intraokularnog, transdermalnog, oralnog ili mnhalacijskog puta primjene.
wherein Ar is as defined in formula (I) and P1 is hydrogen or a protective group (eg. tert-butyldimethyl silyl) in the presence of a base (e.g. potassium carbonate, triethylamine or diisopropylethylamine), followed by removal of the protective group (e.g. using hydrofluoric acid-pyridine complex); or 
(LT) gdje Ar je kako je definirano u formuli (I) i P!" je vodik ili zaštitna skupina u prisutnosti baze, nakon čega slijedi uklanjanje zaštitne skupine; ili kada L' predstavlja vodik, od reakcije spoja sa formulom (IV), ili njegove soli,
an ambient light detector which generates an ambient light level being an indication of an ambient light level; wherein the plurality of illumination devices are arranged to switch on the light source in response to the generated motion signal, in case the ambient light level is below a threshold ambient light level, characterised in that illumination device is arranged to switch on in response to a received alarm signal, and 
- < detektor okolne svjetlosti koji određuje razinu okolne rasvjete kao pokazatelj koliko u okolini ima svjetla; gdje je mnoštvo rasvjetnih tijela napravljeno da uključe izvor svjetlosti kao odgovor na dobiveni signal kretanja, za slučaj da je razina okolne svjetlosti niža od granične razine za okolnu rasvjetu, naznačeno time što je rasvjetno tijelo napravljeno da se uključi kao odgovor na primljeni alarmni signal, 1
The compound or a pharmaceutically acceptable salt thereof of any preceding claim, wherein R5 is aryl or heteroaryl, optionally substituted with halo, nitro, amino, cyano, hydroxy, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkoxy, alkylthio, alkylcarbonyl, carboxy, alkoxycarbonyl, sulfonyl, carbonylamino, sulfonylamino, aminocarbonyl, or aminosulfonyl. 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem prethodnom patentnom zahtjevu, naznačen time da R; je aril ili heteroaril, opcionalno supstituiran sa halo, nitro, amino, cijano, hidroksi, alkil, alkenil, alkinil, aril, cikloalkil, heterocikloalkil, heteroaril, alkoksi, alkiltio, alkilkarbonil, karboksi, alkoksikarbonil, sulfonil, karbonilamino, sulfonilamino, aminokarbonil, ili aminosulfonil.
The cyclisation of a compound of formula II, III or IV leads to a compound of formula I in protected form, i.e. a compound of formula I wherein one or more or all amino groups present in the molecule are protected by an amino protecting group. 
Ciklizacija spoja formule II, III ili IV vodi do spoja formule I u zaštićenom obliku, na primjer do spoja formule I u kojoj je jedna ili više prisutnih amino skupina u molekuli zaštićena amino zaštitnom skupinom.